Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Look Inside the Provenge Decision: Who's In Charge at FDA?

This article was originally published in RPM Report

Executive Summary

A lawsuit filed by the non-profit group CareToLive charges that political infighting at FDA led the agency to reject Dendreon’s application for the therapeutic prostate cancer vaccine Provenge. The result, the suit claims, was a "successful coup d'etat" on the part of one senior FDA official and a failure to act decisively by his superioirs. The message, however, is broader: FDA and its staff can expect scathing, and now personal, attacks from all sides for safety and efficay decisions; with charges they are too accepting of safety issues or too demanding on efficacy.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts